ACE-031 vs Follistatin-344

ACE-031 wins for:

• Systemic lean-mass effect and measurable hypertrophy with infrequent (weekly) administration.
• Clean stacking on androgenic and peptide protocols, due to its long half-life and systemic reach.
• Single-molecule simplicity without precise injection site rituals.

Follistatin-344 wins for:

• Targeted, site-specific hypertrophy—ideal for directly addressing lagging muscle groups with local effect.
• Lower systemic side-effect risk at moderate doses, avoiding the facial telangiectasia and nosebleed signal seen with ACE-031.
• Rapid onset, precise control, and flexibility when stacked with IGF-1 LR3 or GH analogs for localized muscle emphasis.

Pick ACE-031 if:

• The protocol calls for systemic myostatin inhibition to drive broad hypertrophy across multiple muscle groups.
• Users want a minimal-injection option—once-weekly or biweekly SC administration.
• The aim is to stack with AAS or other anabolics to break plateaus where training/nutrition are already dialed in.
• A session-limited, exploratory run of 4–8 weeks makes more sense than year-round myostatin suppression.
• There's a need to avoid HPTA impact or additional PCT requirements.

Pick Follistatin-344 if:

• Focused, site-specific muscle growth is the goal (e.g., one muscle stubbornly lags despite systemic cycles).
• Localized hypertrophy is prioritized over systemic effects—e.g., for aesthetics or symmetry correction.
• There is a need to minimize risk of visible vascular side effects like telangiectasia or chronic epistaxis.
• Stack synergy with other growth factors (IGF-1 LR3, MGF, GH fragments) is a priority for a pathway-diverse cycle.
• Microdosing and flexible cycle structure with rapid on/off is preferred.